Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Low-Dose Rapamycin on Senescence Markers and Physical Functioning in Older Adults with Coronary Artery Disease: Results of a Pilot Study.

The Journal of frailty & aging - 1 Jan 2016

Singh M, Jensen M D, Lerman A, Kushwaha S, Rihal C S, Gersh B J, Behfar A, Tchkonia T, Thomas R J, Lennon R J, Keenan L R, Moore A G, Kirkland J L

Abstract excerpt

Rapamycin, an mTOR inhibitor affects senescence through suppression of senescence-associated secretory phenotype (SASP). We studied the safety and feasibility of low-dose rapamycin and its effect on SASP and frailty in elderly undergoing cardiac rehabilitation (CR). 13 patients; 6 (0.5mg), 6 (1.0mg), and 1 patient received 2mg oral rapamycin (serum rapamycin <6ng/ml) daily for 12 weeks. Median age was 73.9±7.5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine CCL2
Share to Frail Elderly

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-8

Share to Matrix Metalloproteinase 3

Share to Percutaneous Coronary Intervention

Share to Plasminogen Activator Inhibitor 1

Share to Sirolimus

Source

Identifiers

PMID: 27883166
DOI: 10.14283/jfa.2016.112

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Effect of Low-Dose Rapamycin on Senescence Markers and Physical Functioning in Older Adults with Coronary Artery Disease: Results of a Pilot Study.PMID 27883166Read ↗

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.Semantic proximity Read ↗

Long-term rapamycin treatment suppresses IL-17-producing gamma delta T cells and blunts neuroinflammation in agingSemantic proximity Read ↗

Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial ResultsSemantic proximity Read ↗

Circulating miRNAs Associated with Frailty in Old People with Cardiovascular Diseases Promote Cellular Senescence and InflammationSemantic proximity Read ↗

Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriersSemantic proximity Read ↗

Role of Maraviroc and/or Rapamycin in Aging Liver ProcessesSemantic proximity Read ↗

Reduction of Premature Aging Markers After Gastric Bypass Surgery in Morbidly Obese PatientsSemantic proximity Read ↗

mTORC1-S6K activation by endotoxin contributes to cytokine up-regulation and early lethality in animals.Semantic proximity Read ↗

Inhibition of IGF-1R prevents ionizing radiation-induced primary endothelial cell senescence.Semantic proximity Read ↗

TORC1 inhibition as an immunotherapy to reduce infections in the elderlySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.